Albireo Pharma, Inc. entered into an Agreement and Plan of Merger, by and among the Company, Ipsen Biopharmaceuticals, Inc. and wholly owned subsidiary of Ipsen S.A. and Anemone Acquisition Corp. and wholly owned subsidiary of Parent and, solely for purposes of Sections 9.5, 9.6, 9.8 and 9.11 thereof, Ipsen Pharma SAS, a French société par actions simplifiée. In accordance with the terms of the Merger Agreement, (i) each of Susan Alesina, David Chiswell, Ph.D., Ronald H.W. Cooper, Habib Dable, Michael Gutch, Ph.D., Craig Hopkinson, M.D., Stephanie S. Okey, M.S. and Davey S. Scoon ceased to serve in his or her respective position as a member of the Company's Board of Directors, and any committee thereof effective as of the Effective Time, and (ii) Francois Garnier and Aymeric Le Chatelier, each a director of Merger Sub immediately prior to the Effective Time, became directors of the Company, in each case, effective as of the Effective Time.